SCHEMBL25108756

SCHEMBL25108756

C=C(C(=O)OC)c1cccc2nsnc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.45
▸ MAPT P10636 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ PPARG P37231 1/20 0.45
▸ NCOA2 Q15596 1/20 0.45
▸ NCOA1 Q15788 1/20 0.45
▸ NCOA3 Q9Y6Q9 1/20 0.45
▸ L3MBTL1 Q9Y468 4/20 0.44
▸ POLB P06746 2/20 0.44
▸ CTDSP1 Q9GZU7 1/20 0.44
▸ ALDH1A1 P00352 8/20 0.43
▸ HPGD P15428 8/20 0.43
▸ KDM4E B2RXH2 7/20 0.43
▸ HSD17B10 Q99714 4/20 0.43
▸ CASP1 P29466 2/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ HTT P42858 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25108269 0.78 MEN1 (0.52) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL1019293 0.76 HPGD (0.49) RAB9AMAPTMEN1KMT2ANPSR1
SCHEMBL12956408 0.76 L3MBTL1 (0.58) RAB9AMAPTMEN1KMT2ANPSR1
SCHEMBL3753741 0.75 POLB (0.47) RAB9AMAPTMEN1KMT2ANPSR1
SCHEMBL1338456 0.74 L3MBTL1 (0.61) RAB9AMAPTMEN1KMT2AL3MBTL1
SCHEMBL14392300 0.73 KDM4E (0.53) RAB9AMAPTMEN1KMT2ANPSR1
SCHEMBL12391731 0.72 POLB (0.51) RAB9AMAPTMEN1KMT2ALMNA
SCHEMBL25108830 0.72 PARP1 (0.55) RAB9AMAPTMEN1KMT2ALMNA
SCHEMBL25108740 0.71 TOP2A (0.43) RAB9AMAPTMEN1KMT2ALMNA
SCHEMBL21804921 0.71 MAPT (0.43) RAB9AMAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, USP19, USP39 RAB9A 210/4885MAPT 2208/4885MEN1 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback